Sensitivity analyses A separate analysis was performed for this website probable and for possible check details MG patients. In a second sensitivity analysis, we excluded all patients and their matched subjects who had ever been prescribed a bisphosphonate, selective oestrogen receptor modulator, strontium ranelate or parathyroid hormone
during follow-up. Patients were followed for a median of 4 years.
Table 1 Baseline characteristics of patients with incident myasthenia gravis and control patients MG patients Controls Probable MG patients Possible MG patients Characteristics (n = 1,066) (n = 6,392) (n = 834) (n = 232) Female 49.7 49.8 45.6 64.7 Mean age (years) 61.6 61.4 62.4 58.4 BMI (%) <20 5.2 5.5 4.3 8.2 >30 21.5 16.6 22.9 16.4 Unknown 13.0 15.5 12.6 14.7 Smoking status (%) Never 47.7 43.2 46.6 51.7 Current 13.8 17.6 13.5 14.7 Ex 23.2 22.0 25.5 14.7 Unknown 15.3 17.1 14.3 19.0 Alcohol status (%) Never 14.7 10.4 15.2 12.9 Current 57.5 59.6 57.6 57.3 Ex 5.5 3.9 6.0 3.9 Unknown 22.2 26.1 21.2 25.9 Fracture history (%) Any fracture 15.1 15.7 15.0 15.5 Fracture at osteoporotic sites 6.8 7.5 6.7 6.9 Hip fracture 0.8 0.6 0.8 0.4 Vertebral fracture 0.8 0.6 0.5 0.9 Radius/ulna AZD9291 cell line fracture 2.8 3.9 2.6 3.4 Comorbidity ever before index
date (%) Asthma 13.1 10.5 12.8 14.2 COPD 3.0 4.2 3.1 2.6 Congestive heart failure 2.3 2.9 2.0 3.4 Diabetes mellitus 7.9 6.9 8.8 4.7 Rheumatoid arthritis 2.6 1.3 2.8 2.2 Renal failure 1.1 0.9 1.2 0.9 Cerebrovascular disease 8.0 6.1 8.8 5.2 Inflammatory bowel disease 0.8 0.8 0.7 1.3 Cancer 18.3 18.1 18.6 17.2 Thyroid disorders 18.7 11.0 18.0 21.1 Secondary osteoporosis 6.6 4.5 6.5 6.9 Drug use in 6 months before index date (%) Pyridostigmine 13.0 0.0 16.5 0.4 Oral glucocorticoids 8.7 2.8 9.2 6.9 Immunosuppressantsa 2.2 0.4 2.8 0.0 Antidepressants 10.4 8.4 CYTH4 10.9 8.6 Antipsychotics 1.2 1.3 1.2 1.3 Anxiolytics 8.4 5.9 7.4 12.1 Anticonvulsants 3.3 1.8 3.2 3.4 Bisphosphonates 4.1 1.8 4.2 3.9 Hormone replacement therapy 1.9 1.7 1.6 3.0 aCiclosporin, azathioprine, tacrolimus, mycophenolate mofetil and methotrexate are included When compared with their matched controls, patients with a diagnosis of MG had no increased risk of either all fractures in both unadjusted and adjusted models (adjusted hazard ratio (AHR) for any fracture 1.11 (95 % confidence interval [CI] 0.84–1.47) or typical osteoporotic fractures AHR 0.98 (95 % CI 0.67–1.41); Table 2.